Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BGM0504 Tablets
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688166)"BrightGene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BGM0504 Tablets
Filed with SSE · Stock code 688166 · · 2 pages · Chinese
Summary by 6ix AI
The filing also includes important risk warnings regarding the drug development process and potential impacts on the company's operations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
BrightGene Bio-Medical Technology Co. Ltd. on 6ix
Story so far
Earlier from BrightGene Bio-Medical Technology
- Announcement on Resolutions of the 25th Meeting of the 4th Board of Directors
- Announcement on Results of Shareholding Reduction by Shareholder
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Semi-annual Report for 2026
- Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss Indication
Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.
Follow BrightGene Bio-Medical Technology